Literature DB >> 12562273

Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?

Offie Porat Soldin1, Ronald J Elin, Steven J Soldin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12562273      PMCID： PMC3634327          DOI： 10.5858/2003-127-102-TDMIHI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN： 0003-9985            Impact factor:   5.534


× No keyword cloud information.
  27 in total

1.  Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry.

Authors:  Andrew Volosov; Christopher Alexander; Lillian Ting; Steven J Soldin
Journal:  Clin Biochem       Date:  2002-03       Impact factor: 3.281

Review 2.  Critical issues in therapeutic drug monitoring of antiretroviral drugs.

Authors:  Rolf P G Van Heeswijk
Journal:  Ther Drug Monit       Date:  2002-06       Impact factor: 3.681

3.  Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study.

Authors:  C Junghans; N Low; P Chan; A Witschi; P Vernazza; M Egger
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

Review 4.  Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection.

Authors:  D J Back; S H Khoo; S E Gibbons; M G Barry; C Merry
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

5.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study.

Authors:  T P Moyer; Z Temesgen; R Enger; L Estes; J Charlson; L Oliver; A Wright
Journal:  Clin Chem       Date:  1999-09       Impact factor: 8.327

7.  Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.

Authors:  B M Sadler; C Gillotin; Y Lou; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 8.  Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.

Authors:  J G Gerber
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

9.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

10.  Variability in zidovudine serum concentrations.

Authors:  C V Fletcher; H H Balfour
Journal:  Pharmacotherapy       Date:  1996 Nov-Dec       Impact factor: 4.705
View more
  2 in total

1.  Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.

Authors:  Salvador E Cabrera; Dolores Santos; María P Valverde; Alfonso Domínguez-Gil; Francisco González; Guillermo Luna; María J García
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

Review 2.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.